One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Melflufen for the treatment of multiple myeloma
Enrique M. Ocio, Omar Nadeem, Fredrik Schjesvold, Francesca Gay, Cyrille Touzeau, Meletios A. Dimopoulos, Paul G. Richardson & Maria-Victoria Mateos
doi : 10.1080/17512433.2022.2075847
Melphalan flufenamide (melflufen) is a first-in-class peptide–drug conjugate that takes advantage of increased aminopeptidase activity inside tumor cells to rapidly release alkylating agents therein. Melflufen in combination with dexamethasone has been evaluated in multiple clinical trials in patients with relapsed/refractory multiple myeloma (MM).
Givosiran for the treatment of acute hepatic porphyria
Andrea Ricci & Paolo Ventura
doi : 10.1080/17512433.2022.2075848
Acute hepatic porphyrias (AHPs) are a family of rare inherited disorders characterized by enzyme dysfunctions in the hepatic pathway of heme biosynthesis. In AHPs, accumulation of the neurotoxic porphyrin precursors delta-aminolevulinic acid and porphobilinogen, caused by enhanced activity of hepatic aminolevulinate synthase 1 (ALAS1), is associated with acute, potentially life-threatening neurovisceral attacks. Symptoms during and between attacks dramatically reduce patients’ quality of life (QoL). Givosiran is the first mRNA-targeted treatment for AHPs, silencing ALAS1 expression.
Safety and efficacy of therapies for chylomicronemia
Isabel Shamsudeen & Robert A. Hegele
doi : 10.1080/17512433.2022.2094768
Primary chylomicronemia is characterized by pathological accumulation of chylomicrons in the plasma causing severe hypertriglyceridemia, typically >10Â mmol/L (>875 mg/dL). Patients with the ultra-rare familial chylomicronemia syndrome (FCS) subtype completely lack lipolytic capacity and respond minimally to traditional triglyceride-lowering therapies. The mainstay of treatment is a low-fat diet, which is difficult to follow and compromises quality of life. New therapies are being developed primarily to prevent episodes of life-threatening acute pancreatitis.
Why is diagnosis, investigation, and improved management of kidney stone disease important? Non-pharmacological and pharmacological treatments for nephrolithiasis
Viola D’Ambrosio, Shabbir Moochhala, Robert J Unwin & Pietro Manuel Ferraro
doi : 10.1080/17512433.2022.2082943
Progress in the medical treatment and management of nephrolithiasis has been limited to date and continues to depend on urinary metabolic screening to assess excretion of the main stone constituents, factors determining stone solubility and precipitation, and on dietary and lifestyle recommendations.
Systematic reviews of randomized controlled trials of cannabinoid products in chronic pain conditions and for symptoms associated with multiple sclerosis: what do they tell us?
Carlos Vila Silván, Claude Vaney & Igor Dykukha
doi : 10.1080/17512433.2022.2088501
To investigate whether published systematic reviews of randomized controlled trials provide sufficient clarity to inform prescribing of medicinal cannabinoid products, we examined their features and findings in two well-researched areas: chronic cancer/noncancer pain and multiple sclerosis (MS)-related symptoms.
The efficacy of vitamin D in treatment of fibromyalgia: a meta-analysis of randomized controlled studies and systematic review
Kang Qu, Ming-Xi Li, Yu-Ling Zhou, Peng Yu & Ming Dong
doi : 10.1080/17512433.2022.2081151
Recent studies have found potential benefits of vitamin D in relieving pain, and the results from randomized controlled trials of vitamin D for fibromyalgia have been promising. We conducted a comprehensive systematic review and meta-analysis to evaluate the efficacy of vitamin D for treating fibromyalgia.
Effect of statin treatment on homocysteine concentrations: an updated systematic review and meta-analysis with meta-regression
Angelo Zinellu & Arduino A Mangoni
doi : 10.1080/17512433.2022.2072293
Statins might exert atheroprotective effects through lowering the pro-atherogenic amino acid homocysteine. We conducted an updated systematic review and meta-analysis of the effect of statins on circulating homocysteine.
Population pharmacokinetics of omeprazole in obese and normal-weight adults
Kaifeng Chen, Ping Luo, Guoping Yang, Shaihong Zhu, Chenhui Deng, Junjie Ding, Yaqi Lin, Liyong Zhu & Qi Pei
doi : 10.1080/17512433.2022.2075343
Obesity is related to many pathophysiological changes that may result in altered drug disposition. Omeprazole is the most common option utilized for acid-related disorders ; however, the pharmacokinetic (PK) and dosing recommendations for the obese patient population are lacking.
UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions
Michael Harris, Simon Erridge, Mehmet Ergisi, Devaki Nimalan, Michal Kawka, Oliver Salazar, Rayyan Ali, Katerina Loupasaki, Carl Holvey, Ross Coomber, Azfer Usmani, Mohammed Sajad, Jonathan Hoare, James J Rucker, Michael Platt & Mikael H Sodergren
doi : 10.1080/17512433.2022.2017771
To explore pain-specific, general health-related quality of life (HRQoL), and safety outcomes of chronic pain patients prescribed cannabis-based medicinal products (CBMPs).
UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder
Mehmet Ergisi, Simon Erridge, Michael Harris, Michal Kawka, Devaki Nimalan, Oliver Salazar, Katerina Loupasaki, Rayyan Ali, Carl Holvey, Ross Coomber, Michael Platt, James J Rucker & Mikael H Sodergren
doi : 10.1080/17512433.2022.2020640
Anxiety disorders are one of the most common reasons for seeking treatment with cannabis-based medicinal products (CBMPs). Current pharmacological treatments are variable in efficacy and the endocannabinoid system has been identified as a potential therapeutic target. This study aims to detail the changes in health-related quality-of-life (HRQoL) and clinical safety following CBMP therapy for generalized anxiety disorder.
